BRUSSELS, 10 November 2026 – The European Association of Hospital Pharmacists (EAHP) and Abbott, the global healthcare leader, have announced a new innovation partnership to advance education, scientific dialogue and international knowledge exchange among hospital pharmacists, with a focus on supporting patient access to biologic medicines in emerging markets.
The innovation partnership builds on previous work involving EAHP and Abbott, including the EAHP Global Pharmacist Roundtable on biosimilars, held alongside the 30th EAHP Congress in 2026. The initiative brought together leading hospital pharmacists from Europe and emerging markets to exchange practical experience on biosimilar adoption and patient access. The dialogue has since continued through EAHP educational communications, including an editorial in the European Journal of Hospital Pharmacy. The existing program has consistently focused on education, collaboration and sharing pharmacists’ practical experience to help improve access to biologic medicines.
As the use of biologic medicines increases, ensuring broader and sustainable access remains an important challenge for healthcare systems. More than one-third of global medicines spending is estimated to be on biologics by 2027, while biosimilars could generate more than $100 billion in potential annual global savings in 2026, creating an opportunity for healthcare systems to extend access to these treatments within existing budgets.[1]
Hospital pharmacists occupy a unique position within healthcare systems, serving as patient advocates and trusted partners to physicians. Beyond medicines management, they play an important role in shaping patient access to biologics and biosimilars through formulary inclusion, procurement strategies, treatment protocols and the implementation of switching policies, in line with applicable national rules.
Through the innovation partnership, Abbott will support EAHP’s efforts to strengthen education, scientific dialogue and international knowledge exchange among hospital pharmacists on biologic medicines and biosimilars, which may include accredited education, expert exchange between Europe and emerging markets, and opportunities for pharmacists in emerging markets to participate in EAHP scientific activities.
By sharing evidence and practical experience on biosimilar selection, procurement and implementation, the innovation partnership aims to help address barriers to adoption and support their appropriate use in healthcare systems. This may contribute to broader, more sustainable access to biologic medicines, as biosimilars offer healthcare systems an opportunity to manage treatment costs and potentially enable more patients to benefit from biologic therapies within existing healthcare budgets.
“Hospital pharmacists are increasingly connected across borders, and many of the challenges facing our profession are shared. This partnership will help create new opportunities for education, knowledge exchange and collaboration between hospital pharmacists working in different healthcare systems. We are pleased to welcome Abbott as an EAHP Innovation Partner and look forward to a collaboration that supports the continued development of our profession and, ultimately, better care for patients.” said Nenad Miljkovic, President of EAHP.
“Expanding access to medicines, including biologic therapies, requires more than making treatments available. It requires confidence, education and effective implementation across healthcare systems. By supporting EAHP’s efforts to advance knowledge exchange among hospital pharmacists, we can help share practical approaches to addressing barriers to access and adoption, including for biosimilars, and, ultimately, enable more patients to benefit from advances in healthcare,” said Igor Solev, Global Head of Market Access Policy & External Payor Affairs at Abbott.
Looking ahead, the innovation partnership will promote cross-market learning among hospital pharmacists, helping translate practical experience into approaches that can support biosimilar adoption in emerging markets. Through education and scientific dialogue, EAHP aims to help address implementation barriers, strengthen confidence in biosimilars and ultimately expand sustainable patient access to biologic medicines.
ENDS
- Accelerating biosimilar adoption by empowering hospital pharmacists: a dialogue between emerging markets and European hospital pharmacists. European Journal of Hospital Pharmacy. 2026;33(5):393. Available at: https://ejhp.bmj.com/content/33/5/393